首页 中华老年医学杂志 2025年44卷02期 老年前列腺癌临床诊治专家共识(2024版)
中华老年医学杂志
期刊首页
过刊列表
高级检索
稿件发表
• 标准与规范 •
ENGLISH ABSTRACT
老年前列腺癌临床诊治专家共识(2024版)
逄城
钟秋子
朱刚
刘明 
中华医学会老年医学分会
作者及单位信息
·
DOI： 10.3760/cma.j.issn.0254-9026.2025.02.001
Chinese expert consensus on the diagnosis and management of prostate cancer in the elderly(2024 edition)
Pang Cheng
Zhong Qiuzi
Zhu Gang
Liu Ming
Chinese Medical Association Geriatrics
Authors Info & Affiliations
Pang Cheng
Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Zhong Qiuzi
Department of Radiotherapy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Zhu Gang
Department of Urology, Beijing United Family Hospital and Clinics, Beijing 100101, China
Liu Ming
Department of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
Chinese Medical Association Geriatrics
·
DOI： 10.3760/cma.j.issn.0254-9026.2025.02.001
0
0
0
0
0
0
扫描转手机阅读
下载中华医学期刊APP阅读更流畅 体验更丰富
PDF下载
APP内阅读
摘要
我国老龄化形势日益严峻，增龄成为我国老年人群前列腺癌疾病发生发展的独立危险因素。老年前列腺癌患者通常具有身体机能减退、合并症较多等特点，诊断治疗方面与非老年人群存在一定差异。了解和掌握老年前列腺癌患者的特点与临床诊治流程，有助于规范并提高诊疗水平。本共识根据我国老年前列腺癌患者诊治现状与国内外相关指南，总结了老年前列腺癌患者一般健康状况评估方法，并从局限性前列腺癌、晚期前列腺癌及老年前列腺癌患者支持治疗等方面给出了相关共识意见，为医务人员正确评估老年前列腺癌患者健康状况，并进行有效干预及管理提供指导意见。
前列腺;治疗;前列腺癌;专家共识
ABSTRACT
The aging demographic in China raises significant concerns, as advanced age has been identified as an independent risk factor for the onset and progression of prostate cancer among the elderly population.Patients with prostate cancer in this age group often exhibit reduced physical functionality and a higher prevalence of comorbidities, leading to notable differences in their diagnosis and treatment compared to younger patients.A comprehensive understanding of the unique characteristics, as well as the clinical diagnostic and treatment protocols for elderly prostate cancer patients, is essential for standardizing and enhancing the quality of care.This consensus, informed by the current state of diagnosis and treatment for elderly prostate cancer patients in China, along with relevant guidelines from both domestic and international sources, outlines methods for assessing the general health status of these patients.It also provides guidance on the management of localized and advanced prostate cancer, in addition to supportive care for elderly patients.The consensus aims to assist healthcare professionals in accurately evaluating the health status of elderly prostate cancer patients and implementing effective interventions and management strategies.
Prostate;Therapy;Prostate cancer;Expert consensus
Liu Ming, Email:
mocdef.3ab6192013791gnimuil
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文
逄城,钟秋子,朱刚,等. 老年前列腺癌临床诊治专家共识(2024版)[J]. 中华老年医学杂志,2025,44(02)：107-116.
DOI:10.3760/cma.j.issn.0254-9026.2025.02.001PERMISSIONS
Request permissions for this article from CCC.
评价本文
*以上评分为匿名评价
本文评分
5分
[累计个]
向我们报错
版权归中华医学会所有。
未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。
除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。
前列腺癌主要发生于老年男性，其发病率随年龄增加而逐渐升高，2017年全球70%以上前列腺癌患者年龄大于64岁，小于55岁患者多发生于有家族遗传背景者，80%的前列腺癌死亡病例大于65岁
[
1
]。根据我国肿瘤登记数据显示，我国前列腺癌平均发病年龄为72.35岁，50岁以下前列腺癌发病构成比较2000年无明显变化，但是50岁以后前列腺癌发病率开始快速升高，患者主要集中在65岁以上，到80岁以上年龄组达到高峰
[
2
]。
老年前列腺癌患者通常合并症较多，使得前列腺癌的治疗更加复杂。临床研究通常很少纳入高龄老年患者，因此老年前列腺癌群体的新型药物或治疗手段的循证医学证据有限。本共识由国内泌尿外科、老年医学科、放疗科、肿瘤内科等领域专家组成共识专家工作组，参考国内外有关规则、标准或规范，结合国际研究以及我国老年前列腺癌特点制订本共识，为我国临床泌尿外科及肿瘤科医生制定一项基于证据的专家共识，为老年前列腺癌患者提供更多临床可行的诊疗选择。
目前我国暂时没有针对老年前列腺癌患者的诊疗指南。本共识参考世界卫生组织老年人定义，将年龄≥65岁的患者定义为老年前列腺癌患者，并将其作为本共识的目标人群。补充本共识的目标人群。本共识使用人群为临床医生、护理人员及相关教学、科研工作者。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
已是订阅账户?
登录
参考文献
[1]
Zhai Z ， Zheng Y ， Li N ，et al. Incidence and disease burden of prostate cancer from 1990 to 2017：results from the Global Burden of Disease Study 2017[J]. Cancer， 2020，126(9)：1969-1978. DOI：
10.1002/cncr.32733
.
[2]
孙可欣，郑荣寿，顾秀瑛，等. 2000—2014年中国肿瘤登记地区女性乳腺癌发病趋势及年龄变化情况分析[J]. 中华预防医学杂志， 2018，52(6)：567-572. DOI：
10.3760/cma.j.issn.0253-9624.2018.06.003
.
Sun KX ， Zheng RS ， Gu XY ，et al. Incidence trend and change in the age distribution of female breast cancer in cancer registration areas of China from 2000 to 2014[J]. Chin J Prev Med， 2018，52(6)：567-572. DOI：
10.3760/cma.j.issn.0253-9624.2018.06.003
.
[3]
Cohen HJ . Evolution of geriatric assessment in oncology[J]. J Oncol Pract， 2018，14(2)：95-96. DOI：
10.1200/jop.18.00017
.
[4]
Schaeffer EM ， Srinivas S ， Adra N ，et al. Prostate cancer，version 4.2023，NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw， 2023，21(10)：1067-1096. DOI：
10.6004/jnccn.2023.0050
.
[5]
Blagden SP ， Charman SC ， Sharples LD ，et al. Performance status score：Do patients and their oncologists agree？[J]. Br J Cancer， 2003，89(6)：1022-1027. DOI：
10.1038/sj.bjc.6601231
.
[6]
Bellera CA ， Rainfray M ， Mathoulin-Pelissier S ，et al. Screening older cancer patients：first evaluation of the G-8 geriatric screening tool[J]. Ann Oncol， 2012，23(8)：2166-2172. DOI：
10.1093/annonc/mdr587
.
[7]
Droz JP ， Aapro M ， Balducci L ，et al. Management of prostate cancer in older patients：updated recommendations of a working group of the International Society of Geriatric Oncology[J]. Lancet Oncol， 2014，15(9)：e404-e414. DOI：
10.1016/S1470-2045(14)70018-X
.
[8]
Soubeyran P ， Bellera C ， Goyard J ，et al.
Screening for vulnerability in older cancer patients：the ONC
ODAGE Prospective Multicenter Cohort Study
[J]. PLoS One， 2014，9(12)：e115060. DOI：
10.1371/journal.pone.0115060
.
[9]
Boyle HJ ， Alibhai S ， Decoster L ，et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients[J]. Eur J Cancer， 2019，116：116-136. DOI：
10.1016/j.ejca.2019.04.031
.
[10]
Kirkhus L , Jordhøy M ， Šaltytė Benth J ,et al. Comparing comorbidity scales：attending physician score versus the Cumulative Illness Rating Scale for Geriatrics[J]. J Geriatr Oncol， 2016，7(2)：90-98.
10.1016/j.jgo.2015.12.003
.
[11]
Heidenreich A ， Aus G ， Bolla M ，et al. EAU guidelines on prostate cancer[J]. Eur Urol， 2008，53(1)：68-80. DOI：
10.1016/j.eururo.2007.09.002
.
[12]
University of california eprognosis：electronic tools[EB/OL]. 2018. https://EprognosisUcsfEdu/IndexPhp.
[13]
Sun L ， Caire AA ， Robertson CN ，et al. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras[J]. J Urol， 2009，182(5)：2242-2248. DOI：
10.1016/j.juro.2009.07.034
.
[14]
Joniau S ， Briganti A ， Gontero P ，et al. Stratification of high-risk prostate cancer into prognostic categories：a European multi-institutional study[J]. Eur Urol， 2015，67(1)：157-164. DOI：
10.1016/j.eururo.2014.01.020
.
[15]
Bill-Axelson A ， Holmberg L ， Garmo H ，et al. Radical prostatectomy or watchful waiting in early prostate cancer[J]. N Engl J Med， 2014，370(10)：932-942. DOI：
10.1056/NEJMoa1311593
.
[16]
Bill-Axelson A ， Holmberg L ， Garmo H ，et al. Radical prostatectomy or watchful waiting in prostate cancer-29-year follow-up[J]. N Engl J Med， 2018，379(24)：2319-2329. DOI：
10.1056/NEJMoa1807801
.
[17]
Bill-Axelson A ， Holmberg L ， Filén F ，et al. Radical prostatectomy versus watchful waiting in localized prostate cancer：the Scandinavian prostate cancer group-4 randomized trial[J]. J Natl Cancer Inst， 2008，100(16)：1144-1154. DOI：
10.1093/jnci/djn255
.
[18]
Magheli A ， Rais-Bahrami S ， Humphreys EB ，et al. Impact of patient age on biochemical recurrence rates following radical prostatectomy[J]. J Urol， 2007，178(5)：1933-1937；discussion 1937-1938.DOI：
10.1016/j.juro.2007.07.016
.
[19]
Siddiqui SA ， Sengupta S ， Slezak JM ，et al. Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer[J]. J Urol， 2006，175(3)：Pt 1-952. 957DOI：
10.1016/s0022-5347(05)00339-3
.
[20]
Malaeb BS ， Rashid HH ， Lotan Y ，et al. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts[J]. Urol Oncol， 2007，25(4)：291-297. DOI：
10.1016/j.urolonc.2006.08.001
.
[21]
Stanford JL ， Feng Z ， Hamilton AS ，et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer：the Prostate Cancer Outcomes Study[J]. JAMA， 2000，283(3)：354-360. DOI：
10.1001/jama.283.3.354
.
[22]
Mohamad BA ， Marszalek M ， Brossner C ，et al.
Radical p
rostatectomy in Austria：A nationwide analysis of 16，524 cases
[J]. Eur Urol， 2007，51(3)：684-648；discussion 689.DOI：
10.1016/j.eururo.2006.06.022
.
[23]
Hu JC ， Elkin EP ， Pasta DJ ，et al. Predicting quality of life after radical prostatectomy：results from CaPSURE[J]. J Urol， 2004，171(2)：Pt 1-703. 708DOI：
10.1097/01.ju.0000107964.61300.f6
.
[24]
Basto MY ， Vidyasagar C ， te Marvelde L ，et al. Early urinary continence recovery after robot-assisted radical prostatectomy in older Australian men[J]. BJU Int， 2014，114：Suppl 1-29. 33DOI：
10.1111/bju.12800
.
[25]
黄健．中国泌尿外科和男科疾病诊断治疗指南[M]. 2019版．北京：科学出版社， 2020.
Huang J ．Guidelines for diagnosis and treatment of urology and andrology diseases in China[M]. 2019 edition. Beijing：Science Press， 2020.
[26]
Peeters ST ， Heemsbergen WD ， Koper PC ，et al. Dose-response in radiotherapy for localized prostate cancer：results of the Dutch multicenter randomized phase Ⅲ trial comparing 68 Gy of radiotherapy with 78 Gy[J]. J Clin Oncol， 2006，24(13)：1990-1996. DOI：
10.1200/JCO.2005.05.2530
.
[27]
Pollack A ， Zagars GK ， Starkschall G ，et al. Prostate cancer radiation dose response：results of the M．D.Anderson phase Ⅲ randomized trial[J]. Int J Radiat Oncol Biol Phys， 2002，53(5)：1097-105. DOI：
10.1016/s0360-3016(02)02829-8
.
[28]
Zietman AL ， DeSilvio ML ， Slater JD ，et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate：a randomized controlled trial[J]. JAMA， 2005，294(10)：1233-1239. DOI：
10.1001/jama.294.10.1233
.
[29]
Kuban DA ， Tucker SL ， Dong L ，et al. Long-term results of the M．D.Anderson randomized dose-escalation trial for prostate cancer[J]. Int J Radiat Oncol Biol Phys， 2008，70(1)：67-74. DOI：
10.1016/j.ijrobp.2007.06.054
.
[30]
Wilson JM ， Dearnaley DP ， Syndikus I ，et al. The efficacy and safety of conventional and hypofractionated high-dose radiation therapy for prostate cancer in an elderly population：A subgroup analysis of the CHHiP trial[J]. Int J Radiat Oncol Biol Phys， 2018，100(5)：1179-1189. DOI：
10.1016/j.ijrobp.2018.01.016
.
[31]
Liu L ， Glicksman AS ， Coachman N ，et al. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer[J]. Int J Radiat Oncol Biol Phys， 1997，38(1)：65-71. DOI：
10.1016/s0360-3016(96)00580-9
.
[32]
Schultheiss TE ， Hanks GE ， Hunt MA ，et al. Incidence of and factors related to late complications in conformal and conventional radiation treatment of cancer of the prostate[J]. Int J Radiat Oncol Biol Phys， 1995，32(3)：643-649. DOI：
10.1016/0360-3016(95)00149-s
.
[33]
Skwarchuk MW ， Jackson A ， Zelefsky MJ ，et al. Late rectal toxicity after conformal radiotherapy of prostate cancer(Ⅰ)：multivariate analysis and dose-response[J]. Int J Radiat Oncol Biol Phys， 2000，47(1)：103-113. DOI：
10.1016/s0360-3016(99)00560-x
.
[34]
Chen AB ，
<x>D</x>
<x>'</x>
<x>Amico</x>
AV ， Neville BA ，et al. Patient and treatment factors associated with complications after prostate brachytherapy[J]. J Clin Oncol， 2006，24(33)：5298-5304. DOI：
10.1200/JCO.2006.07.9954
.
[35]
Pinkawa M ， Fischedick K ， Gagel B ，et al. Impact of age and comorbidities on health-related quality of life for patients with prostate cancer：evaluation before a curative treatment[J]. BMC Cancer， 2009，9：296. DOI：
10.1186/1471-2407-9-296
.
[36]
<x>D</x>
<x>'</x>
<x>Amico</x>
AV ， Chen MH ， Renshaw AA ，et al. Androgen suppression and radiation vs radiation alone for prostate cancer：a randomized trial[J]. JAMA， 2008，299(3)：289-295. DOI：
10.1001/jama.299.3.289
.
[37]
<x>D</x>
<x>'</x>
<x>Amico</x>
AV ， Chen MH ， Renshaw A ，et al. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer[J]. JAMA， 2015，314(12)：1291-1293. DOI：
10.1001/jama.2015.8577
.
[38]
Giacalone NJ ， Wu J ， Chen MH ，et al. Prostate-specific antigen failure and risk of death within comorbidity subgroups among men with unfavorable-risk prostate cancer treated in a randomized trial[J]. J Clin Oncol， 2016，34(31)：3781-3786. DOI：
10.1200/JCO.2016.68.4530
.
[39]
Widmark A ， Klepp O ， Solberg A ，et al. Endocrine treatment，with or without radiotherapy，in locally advanced prostate cancer(SPCG-7/SFUO-3)：an open randomised phase Ⅲ trial[J]. Lancet， 2009，373(9660)：301-308. DOI：
10.1016/S0140-6736(08)61815-2
.
[40]
Hoffman KE ， Chen MH ， Moran BJ ，et al. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer[J]. Cancer， 2010，116(11)：2590-2595. DOI：
10.1002/cncr.24974
.
[41]
Albertsen PC . Observational studies and the natural history of screen-detected prostate cancer[J]. Curr Opin Urol， 2015，25(3)：232-237. DOI：
10.1097/MOU.0000000000000157
.
[42]
Valerio M ，
<x>Ceranto</x>
<x>la</x>
Y ， Eggener SE ，et al. New and established technology in focal ablation of the prostate：a systematic review[J]. Eur Urol， 2017，71(1)：17-34. DOI：
10.1016/j.eururo.2016.08.044
.
[43]
Zhang K ， Teoh J ， Laguna P ，et al. Effect of focal vs extended irreversible electroporation for the ablation of localized low-or intermediate-risk prostate cancer on early oncological control：a randomized clinical trial[J]. JAMA Surg， 2023，158(4)：343-349. DOI：
10.1001/jamasurg.2022.7516
.
[44]
Sammon JD ， Abdollah F ， Reznor G ，
et
al
. Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer[J]. Eur Urol， 2015，68(1)：32-39. DOI：
10.1016/j.eururo.2014.10.018
.
[45]
Lu-Yao GL ， Albertsen PC ， Moore DF ，et al. Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer[J]. JAMA Intern Med， 2014，174(9)：1460-1467. DOI：
10.1001/jamainternmed.2014.3028
.
[46]
Potosky AL ， Haque R ， Cassidy-Bushrow AE ，et al. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer[J]. J Clin Oncol， 2014，32(13)：1324-1330. DOI：
10.1200/JCO.2013.52.5782
.
[47]
Eastham JA ， Auffenberg GB ， Barocas DA ，et al. Clinically Localized Prostate Cancer：AUA/ASTRO Guideline，Part Ⅰ：Introduction，Risk Assessment，Staging，and Risk-Based Management[J]. J Urol， 2022，208(1)：10-18. DOI：
10.1097/JU.0000000000002757
.
[48]
Konety BR ，
<x>Cowan JE</x>
<x>&</x>
<x>Carroll</x>
PR . Patterns of primary and secondary therapy for prostate cancer in elderly men：analysis of data from CaPSURE[J]. J Urol， 2008，179(5)：1797-1803. DOI：
10.1016/j.juro.2008.01.044
.
[49]
Cornford P ， van den Bergh RCN ， Briers E ，et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer.Part Ⅱ-2020 Update：Treatment of Relapsing and Metastatic Prostate Cancer[J]. Eur Urol， 2021，79(2)：263-282. DOI：
10.1016/j.eururo.2020.09.046
.
[50]
Loblaw DA ， Virgo KS ， Nam R ，et al. Initial Hormonal Management of Androgen-sensitive Metastatic，Recurrent，or Progressive Prostate Cancer：2006 Update of an American Society of Clinical Oncology practice Guideline[J]. J Clin Oncol， 2007，25(12)：1596-1605. DOI：
10.1200/JCO.2006.10.1949
.
[51]
Lowrance WT ， Breau RH ， Chou R ，et al. Advanced prostate cancer：AUA/ASTRO/SUO Guideline PART Ⅰ[J]. J Urol， 2021，205(1)：14-21. DOI：
10.1097/JU.0000000000001375
.
[52]
Kyriakopoulos CE ， Chen YH ， Carducci MA ，et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer：long-term survival analysis of the randomized phase Ⅲ E3805 CHAARTED Trial[J]. J Clin Oncol， 2018，36(11)：1080-1087. DOI：
10.1200/JCO.2017.75.3657
.
[53]
James ND ， Sydes MR ， Clarke NW ，et al. Addition of docetaxel，zoledronic acid，or both to first-line long-term hormone therapy in prostate cancer(STAMPEDE)：survival results from an adaptive，multiarm，multistage，platform randomised controlled trial[J]. Lancet， 2016，387(10024)：1163-1177. DOI：
10.1016/S0140-6736(15)01037-5
.
[54]
Fizazi K ， Tran N ， Fein L ，et al. Abiraterone plus prednisone in metastatic，castration-sensitive prostate cancer[J]. N Engl J Med， 2017，377(4)：352-360. DOI：
10.1056/NEJMoa1704174
.
[55]
James ND ， de Bono JS ， Spears MR ，et al. Abiraterone for prostate cancer not previously treated with hormone therapy[J]. N Engl J Med， 2017，377(4)：338-351. DOI：
10.1056/NEJMoa1702900
.
[56]
Landre T ， Guetz GD ， Chouahnia K ，et al. Is There a benefit of addition docetaxel，abiraterone，celecoxib，or zoledronic acid in initial treatments for patients older than 70 years with hormone-sensitive advanced prostate cancer? A meta-analysis[J]. Clin Genitourin Cancer， 2019，17(4)：e806-e813. DOI：
10.1016/j.clgc.2019.05.001
.
[57]
Armstrong AJ ， Szmulewitz RZ ， Petrylak DP ，et al.
AR
CHES：a randomized，phase Ⅲ study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
[J]. J Clin Oncol， 2019，37(32)：2974-2986. DOI：
10.1200/JCO.19.00799
.
[58]
Davis ID ， Martin AJ ， Stockler MR ，et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer[J]. N Engl J Med， 2019，381(2)：121-131. DOI：
10.1056/NEJMoa1903835
.
[59]
Burdett S ， Boeve LM ， Ingleby FC ，et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer：a STOPCAP systematic review and meta-analysis[J]. Eur Urol， 2019，76(1)：115-124. DOI：
10.1016/j.eururo.2019.02.003
.
[60]
Smith MR ， Saad F ， Chowdhury S ，et al. Apalutamide treatment and metastasis-free survival in prostate cancer[J]. N Engl J Med， 2018，378(15)：1408-1418. DOI：
10.1056/NEJMoa1715546
.
[61]
Hussain M ， Fizazi K ， Saad F ，et al. Enzalutamide in men with nonmetastatic，castration-resistant prostate cancer[J]. N Engl J Med， 2018，378(26)：2465-2474. DOI：
10.1056/NEJMoa1800536
.
[62]
Fallah J ， Zhang L ， Amatya A ，et al. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors：a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials[J]. Lancet Oncol， 2021，22(9)：1230-1239. DOI：
10.1016/S1470-2045(21)00334-X
.
[63]
Yang DD ， Mahal BA ， Muralidhar V ，et al. Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer[J]. Cancer， 2017，123(24)：4832-4840. DOI：
10.1002/cncr.30948
.
[64]
Ryan CJ ， Cheng ML . Abiraterone acetate for the treatment of prostate cancer[J]. Expert Opin Pharmacother， 2013，14(1)：91-96. DOI：
10.1517/14656566.2013.745852
.
[65]
Beer TM ， Tombal B ．Enzalutamide in metastatic prostate cancer before chemotherapy[J]. N Engl J Med， 2014，371(18)：1755-1756. DOI：
10.1056/NEJMc1410239
.
[66]
de Bono JS ， Logothetis CJ ， Molina A ，et al. Abiraterone and increased survival in metastatic prostate cancer[J]. N Engl J Med， 2011，364(21)：1995-2005. DOI：
10.1056/NEJMoa1014618
.
[67]
Scher HI ， Fizazi K ， Saad F ，et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med， 2012，367(13)：1187-1197. DOI：
10.1056/NEJMoa1207506
.
[68]
Mulders PF ， Molina A ， Marberger M ，et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup(aged 75 and older)with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy[J]. Eur Urol， 2014，65(5)：875-883. DOI：
10.1016/j.eururo.2013.09.005
.
[69]
Sternberg CN ， de Bono JS ， Chi KN ，et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide：results from the phase III AFFIRM trial[J]. Ann Oncol， 2014，25(2)：429-434. DOI：
10.1093/annonc/mdt571
.
[70]
Parker C ， Nilsson S ， Heinrich D ，et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med， 2013，369(3)：213-223. DOI：
10.1056/NEJMoa1213755
.
[71]
George DJ ， Agarwal N ， Sartor O ，et al. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer(EPIX study)[J]. Prostate Cancer Prostatic Dis， 2022，25(2)：306-313. DOI：
10.1038/s41391-021-00488-0
.
[72]
de Bono J ， Mateo J ， Fizazi K ，et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer[J]. N Engl J Med， 2020，382(22)：2091-2102. DOI：
10.1056/NEJMoa1911440
.
[73]
Rhee H ， Gunter JH ， Heathcote P ，et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management[J]. BJU Int， 2015，115：Suppl 5-3. 13DOI：
10.1111/bju.12964
.
[74]
Mohile SG ， Mustian K ， Bylow K ，et al. Management of complications of androgen deprivation therapy in the older man[J]. Crit Rev Oncol Hematol， 2009，70(3)：235-255. DOI：
10.1016/j.critrevonc.2008.09.004
.
[75]
Ahmadi H & Daneshmand S ．Androgen deprivation therapy：evidence-based management of side effects[J]. BJU Int， 2013，111(4)：543-548. DOI：
10.1111/j.1464-410X.2012.11774.x
.
[76]
Solanki AJ ， Kamrava M ， Posadas EM ，et al. A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer[J]. Cancer， 2024，130(11)：1916-1929. DOI：
10.1002/cncr.35285
.
[77]
Dragomir A ， Touma N ， Hu J ，et al. Androgen deprivation therapy and risk of cardiovascular disease in patients with prostate cancer based on existence of cardiovascular risk[J]. J Natl Compr Canc Netw， 2023. 21(2)：163-171. DOI：
10.6004/jnccn.2022.7083
.
[78]
Jayadevappa R ， Chhatre S ， Malkowicz SB ，et al. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer[J]. JAMA Netw Open， 2019，2(7)：e196562. DOI：
10.1001/jamanetworkopen.2019.6562
.
[79]
Formenti AM ， Dalla Volta A ， di Filippo L ，et al. Effects of medical treatment of prostate cancer on bone health[J]. Trends Endocrinol Metab， 2021. 32(3)：135-158. DOI：
10.1016/j.tem.2020.12.004
.
[80]
Jones C ， Gray S ， Brown M ，et al. Risk of fractures and falls in men with advanced or metastatic prostate cancer receiving androgen deprivation therapy and treated with novel androgen receptor signalling inhibitors：a systematic review and meta-analysis of randomised controlled trials[J]. Eur Urol Oncol， 2024，7(5)：993-1004. DOI：
10.1016/j.euo.2024.01.016
.
[81]
Suarez-Almazor ME ， Pundole X ， Cabanillas G ，et al. Association of bone mineral density testing with risk of major osteoporotic fractures among older men receiving androgen deprivation therapy to treat localized or regional prostate cancer[J]. JAMA Netw Open， 2022，5(4)：e225432. DOI：
10.1001/jamanetworkopen.2022.5432
.
[82]
Droz JP ， Albrand G ， Gillessen S ，et al. Management of prostate cancer in elderly patients：recommendations of a task force of the international society of geriatric oncology[J]. Eur Urol， 2017，72(4)：521-531. DOI：
10.1016/j.eururo.2016.12.025
.
[83]
Smith MR ， Saad F ， Egerdie B ，et al. Sarcopenia during androgen-deprivation therapy for prostate cancer[J]. J Clin Oncol， 2012，30(26)：3271-3276. DOI：
10.1200/JCO.2011.38.8850
.
[84]
Campos C ， Sotomayor P ， Jerez D ，et al. Exercise and prostate cancer：From basic science to clinical applications[J]. Prostate， 2018，78(9)：639-645. DOI：
10.1002/pros.23502
.
[85]
Alibhai SM ， Santa Mina D ， Ritvo P ，et al. A phase Ⅱ RCT and economic analysis of three exercise delivery methods in men with prostate cancer on androgen deprivation therapy[J]. BMC Cancer， 2015，15：312. DOI：
10.1186/s12885-015-1316-8
.
备注信息
A
刘明，Email:
mocdef.3ab6192013791gnimuil
B
所有作者声明无利益冲突
C
中央高水平医院临床科研业务费 (BJ-2022-083)
中央高水平医院临床科研业务费 (BJ-2022-115)
评论 （0条）
注册 登录
时间排序
- 时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
我国软组织病理学近十年的回顾与展望
阎晓初 等 中华病理学杂志 2025,54(02)
我国泌尿及男生殖系统病理学近十年的回顾与展望
王小桐 等 中华病理学杂志 2025,54(01)
我国儿科病理学近十年的回顾与展望
张楠 等 中华病理学杂志 2025,54(02)
我国甲状腺病理学近十年的回顾与展望
高洪文 等 中华病理学杂志 2025,54(01)
分享
详细信息
表
访问与引文
阅读权限
参考文献
访问与引用
访问数据
0
0
全部时间 最近30天 最近6个月 最近12个月
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照
文献快照
N/A
N/A
AI总结中
N/A
N/A
快照内容由人工智能生成，供您参考。
你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。
0/50
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
0/2000
信息反馈
中文(简体)
英文
翻译
机器翻译功能由科大讯飞提供技术支持
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
你好！ 今天我能为您提供什么帮助？
0/30
of
很抱歉，当前对话已达到其限制。
使用"新建对话"按钮开启更多对话。
停止回答
扩写 缩写 改写 翻译
0/2000
信息反馈
历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大
翻译
润色
扩写
缩写
复制
引用
